Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    As Oncology Nurses, We Are the Fish
    Oncology nurse pride
    As Oncology Nurses, We Are the Fish
    May 20, 2022
    Patients and the Public Recognize and Thank Dedicated Nurses
    Nurse empowerment
    Patients and the Public Recognize and Thank Dedicated Nurses
    May 06, 2022
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    Cancer screening
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    March 18, 2022
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    Oncology nurse pride
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    February 11, 2022
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    Oncology nurse pride
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    January 31, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Adjuvant therapy

    Adjuvant therapy

    Gene Expression Helps Predict Benefit From Adjuvant Chemo for Breast Cancer

    Although nearly 60% of all patients with early-stage breast cancer are given adjuvant chemotherapy, only 2%–15% of them receive clinical benefit, according to research published in the 2016 American Society of Clinical Oncology Educational Book.
    October 18, 2016
    Adjuvant therapy

    Outpatient Oncology Drug Series: Oxaliplatin Hates the Cold

    Oxaliplatin is a cytotoxic (toxic to normal cells) chemotherapy drug that is classified as an alkylating agent as well as a platinum analogue. It is indicated for a number of different cancers including colorectal, esophageal, gastric, hepatobiliary, Non-Hodgkin lymphoma, ovarian, pancreatic, and testicular cancer.
    January 16, 2015
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲